Pharmacan Announces Restructuring of Its Board of Directors

TORONTO, ON--(Marketwired - January 19, 2016) - PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan" or the "Corporation")

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES

PharmaCan is pleased to announce that it has implemented a change to its Board of Directors reducing the number of serving Board members from seven to five.

Mr. Ari Huber and Mr. Steven Isenberg have tendered their resignations and have stepped down from the Board. Mr. Huber will continue to serve the company in his ongoing role of Chief Financial Officer.

PharmaCan's Chairman Lorne Gertner commented, "I wish to sincerely thank Mr. Huber and Mr. Isenberg for their outstanding performance while serving on the PharmaCan Board. I am grateful for their wise counsel and their tireless commitment to the welfare of the company and all of its stakeholders. I am confident that the recomposed Board will serve the company's long-term interests in an efficient and intelligent manner."

Post restructuring PharmaCan's Board consists of:

Lorne Gertner -- Chairman

Michael Gorenstein -- Vice Chairman

Paul Rosen -- President and CEO

Michael Krestell -- Independent

Alan Friedman -- Independent

About PharmaCan Capital Corp.

PharmaCan is a company in the business of investing in companies either licensed, or actively seeking a license, to produce medical marihuana pursuant to Canada's MMPR. PharmaCan has a diversified portfolio of investments including investments in 5 of the 26 companies licensed by Health Canada to produce medical marihuana.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.